MedTrace Logo

Feasibility Study Testing Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects

NCT02780375 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2018-10-31

No results posted yet for this study

Summary

Peripheral blood samples will be taken with informed consent from radiotherapy patients undergoing standard radiotherapy at The Royal Marsden before and during treatment for breast, lung, gastrointestinal and genitourinary tumours. Responses from panels of up to 800 coding and non-coding RNAs will be assessed in the samples using the nCounter system. Candidate genes identified by Public Health England, Columbia University and/or in the literature as being specific to radiation responses will be included, together with genes relevant to systemic inflammatory responses, to identify transcriptional responses for a range of doses and exposures on an inter-individual basis. Data will be analysed using existing and new statistical tools focused on count data modelling. The intended outcome is identification of a radiation specific panel of genes to inform individual radiation responses and if the results are favourable, a large scale follow up to this proposed pilot is expected in due course.

Conditions

Interventions

PROCEDURE

Blood donation during radiotherapy

Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy

Sponsors & Collaborators

  • Public Health England

    collaborator OTHER_GOV

  • Institute of Cancer Research, United Kingdom

    lead OTHER

Principal Investigators

  • Navita Somaiah · Institute of Cancer Research, United Kingdom

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-12
Primary Completion
2018-07-17
Completion
2018-07-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02780375 on ClinicalTrials.gov